Ganoderol B

Description :

Triterpenoids from Ganoderma lucidum inhibit the activation of EBV antigens as telomerase inhibitors PUMID/DOI：DOI: 10.3892/etm.2017.4883 Exp Ther Med. 2017 Oct;14(4):3273-3278. Nasopharyngeal carcinoma (NPC) is a malignant disease that threatens the health of humans. To find effective agents for the inhibition of Epstein-Barr virus (EBV) infection, which is associated with NPC, a phytochemical investigation of Ganoderma lucidum was carried out in the present study. Five triterpenoids were identified, including ganoderic acid A (compound 1), ganoderic acid B (compound 2), ganoderol B (compound 3), ganodermanontriol (compound 4), and gano-dermanondiol (compound 5), on the basis of spectroscopic analysis. An inhibition of EBV antigens activation assay was implemented to elucidate the triterpenoids from G. lucidum and potentially prevent NPC. All the triterpenoids showed significant inhibitory effects on both EBV EA and CA activation at 16 nmol. At 3.2 nmol, all the compounds moderately inhibited the activation of the two antigens. The activity of telomerase was inhibited by these triterpenoids at 10 mu M. Molecular docking demonstrated that compound 1 was able to inhibit telomerase as a ligand. In addition, the physicochemical properties of these compounds were calculated to elucidate their drug-like properties. These results provided evidence for the application of these triterpenoids and whole G. lucidum in the treatment of NPC. Protective effects of triterpenoids from Ganoderma resinaceum on H2O2-induced toxicity in HepG2 cells PUMID/DOI：DOI: 10.1016/j.foodchem.2013.03.071 Food Chem. 2013 Nov 15;141(2):920-6. Ganoderma resinaceum Boud. (Polyporeseae) has long been used for antioxidant, immunoregulation and liver protection. From the fruiting bodies of G. resinaceum, eight new lanostanoids, lucidones D-G (1-4), 7-oxo-ganoderic acid Z(2) (5), 7-oxo-ganoderic acid Z(3) (6), ganoderesin A (7), and ganoderesin B (8), together with six known lanostanoids (9-14) were isolated. The structures of new compounds were elucidated through extensive spectroscopic analysis. In an in vitro model, ganoderesin B (8), ganoderol B (10) and lucidone A (11) showed inhibitory effects against the increase of ALT and AST levels in HepG2 cells induced by H2O2 compared to a control group in the range of their maximum non-toxic concentration (MNTC). However, compounds 8, 10 and 11 displayed no anti-oxidant activities by DPPH assay. Mean-while, activation for PXR (Pregnane X Receptor) of ganoderesin B (8), ganoderol B (10) and lucidone A (11) was evaluated; ganoderol (10) exhibited a vital activation for PXR-induced CYP3A4 expression. These results suggested that GTs (Ganoderma triterpenoids) exhibited hepatoprotective activities by lowering ALT and AST levels. (C) 2013 Elsevier Ltd. All rights reserved. Ganoderol B: A potent alpha-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum PUMID/DOI：DOI: 10.1016/j.phymed.2011.03.011 Phytomedicine. 2011 Sep 15;18(12):1053-5. alpha-Glucosidase inhibitor has considerable potential as a diabetes mellitus type 2 drug because it prevents the digestion of carbohydrates. The search for the constituents reducing alpha-glucosidase activity led to the finding of active compounds in the fruiting body of Ganoderma lucidum. The CHCl3 extract of the fruiting body of G. lucidum was found to show inhibitory activity on alpha-glucosidase in vitro. The neutral fraction, with an IC50 of 88.7 mu g/ml, had stronger inhibition than a positive control, acarbose, with an IC50 of 336.7 mu g/ml (521.5 mu M). The neutral fraction was subjected to silica gel column chromatography and repeated p-HPLC to provide an active compound, (3 beta,24E)-lanosta-7,9(11),24-trien-3,26-diol (ganoderol B). It was found to have high alpha-glucosidase inhibition, with an IC50 of 48.5 mu g/ml (119.8 mu M). (C) 2011 Elsevier GmbH. All rights reserved. The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum PUMID/DOI：DOI: 10.1016/j.bmc.2007.04.036 Bioorg Med Chem. 2007 Jul 15;15(14):4966-72. The anti-androgenic activity of the ethanol extract of the fruiting body of Ganoderma lucidum has been previously reported. Ganoderol B with 5 alpha-reductase inhibitory activity and the ability to bind to androgen receptor (AR) can inhibit androgen-induced LNCaP cell growth and suppress regrowth of the ventral prostate induced by testosterone in rats. The down-regulation of AR signaling by ganoderol B provides an important mechanism for its anti-androgenic activity. In view of the fact that PSA (prostatic specific antigen, a well-accepted prognostic indicator of prostate cancer) is down-regulated, an important implication of this study is that ganoderol B intervention strategy aimed at toning down the amplitude of androgen signaling could be helpful in controlling morbidity of prostate cancer. In conclusion, our result suggests that ganoderol B might be useful in prostate cancer and benign prostatic hyperplasia (BPH) therapy through suppressing the function of androgen and its receptor. (c) 2007 Elsevier Ltd. All rights reserved.